Metal complexes of bleomycin: Evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy

被引：24

作者：

Brooks, RC

Carnochan, P

Vollano, JF

Powell, NA

Zweit, J

Sosabowski, JK

Martellucci, S

Darkes, MC

Fricker, SP

Murrer, BA

机构：

[1] Royal Marsden Hosp NHS Trust, Joint Dept Phys, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Surrey, England

[3] Johnson Matthey Technol Ctr, Reading, Berks, England

[4] Johnson Matthey Inc, Biomed Res, W Chester, PA USA

来源：

NUCLEAR MEDICINE AND BIOLOGY | 1999年 / 26卷 / 04期

关键词：

targeted radiotherapy; bleomycin; Rhodium-105; pharmacokinetics; biodistribution;

D O I：

10.1016/S0969-8051(98)00109-7

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Bleomycin has been used as a carrier for several radioisotopes; however, its potential for clinical use has been limited either by the in vivo stability of the complexes or the half-life of the isotope used. The chemical, biological, and radiological properties of (105)Rhodium appear to make it an ideal choice for targeted radiotherapy. The synthesis and purification of a hereto unreported (105)Rhodium-bleomycin (Rh-105-BLM) complex is described. The stability of this complex in plasma is sufficient to allow targeted delivery of the radioisotope. (57)Cobalt-bleomycin was studied under identical conditions for comparative purposes. The suitability of Rh-105-BLM for targeted therapy, which appears to be limited by the renal clearance of this agent, is discussed. NUCL MED BIOL 26;4:421-430, 1999. (C) 1999 Elsevier Science Inc. All rights reserved.

引用

页码：421 / 430

页数：10

共 30 条

[1] COBALT-BLEOMYCINS AND DEOXYRIBONUCLEIC-ACID - SEQUENCE-DEPENDENT INTERACTIONS, ACTION SPECTRUM FOR NICKING, AND INDIFFERENCE TO OXYGEN [J].